Lyra Therapeutics enrolls Phase 3 ENLIGHTEN I trial of LYR-210

Lyra Therapeutics announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. Topline results from ENLIGHTEN I are expected in the first half of 2024 as planned. “We are pleased to have fully enrolled the first of our two pivotal trials of LYR-210 in CRS patients,” said Richard Nieman, MD, Chief Medical Officer of Lyra Therapeutics. “Our clinical team is now focusing all of its recruitment efforts on the second of our two pivotal trials, ENLIGHTEN II, for which we expect to complete enrollment in the second half of 2024,” Dr. Nieman continued. “We thank the participants and the investigators in the ENLIGHTEN studies as we advance our technology that could potentially benefit millions of patients with CRS.”